Topotecan in platinum- and paclitaxel-resistant ovarian cancer

Gynecologic Oncology

Volumn 66, Issue 3, 1997, Pages 480-486

  Swisher, Elizabeth M ^a   Mutch, David G ^a   Rader, Janet S ^a   Elbendary, Alaa ^a   Herzog, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031239998     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4787     Document Type: Article

References (26)

1. 1. Mcguire WP, Hoskins WH, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. NEJM 334(1): 1-6, 1996
2. 2. Christian MC, Trimble EL: Salvage therapy for epithelial ovarian carcinoma. Gynecol Oncol 55(Suppl):143-150, 1994
3. 3. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin KS, Jones W, Almadrones L, Lewis JL: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
4. 4. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9(7): 1138-1150, 1991
5. 5. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD: Clinical trials with topoisomerase I inhibitors. Semin Oncol 19(6):663-669, 1992
6. 6. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as anti-tumor agents. J Natl Cancer Inst 85(4):271-291, 1993
7. 7. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH: Phase I trial of lowdose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J CHn Oncol 12(3):553-559, 1994
8. 8. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, A. FA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10(4):647-656, 1992
9. 9. Rustin GJS, Nelstrop ARE, McClean P, Brady MF, McGuire MF, Hoskins WJ, Mitchell H, Lambert HE: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J Clin Oncol 14(5):1545-1551, 1996
10. 10. Rustin GJS, Nelstrop ARE, Crawford M, Lederman J, Lambert HE, Coleman LR, Johnson J, Evans H, Brown S, Oster W: Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA-125. J Clin Oncol 15(1):172-176, 1997
11. 11. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14(12):3056-3061, 1996
12. 12. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzales de Leon C, Kim EE, Madden T, Wallin B, Hard M, Verschraegen C, Raber M, Kavanagh JJ: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J CHn Oncol 14(5): 1552-1557, 1996
13. 13. Murphy B, Saltz L, Sirott M, Young C, Tong W, Trochanowski B, Toomasi F, Kelsen D: Granulocyte-colony stimulating factor (G-CSF) does not increase the maximum tolerated dose (MTD) in a phase I study of topotecan (T). Proc Am Soc Clin Oncol 11:139, 1992 [abstract]
14. 14. Gordon A, Bookman M, Malmstrom H, Bolis G, Mangioni C, Hall J, Carter J, Hudson I, Broom C: Efficacy of topotecan in advanced ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Amer Soc Clin Oncol 15:282, 1996 [abstract]
15. 15. Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y, Saijo N: Mechanisms of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52:328-333, 1992
16. 16. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu L, Saijo N: Establishment of a camptothecin analogue (CPT-11) resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res 50:5919-5924, 1990
17. 17. Kijima T, Kubota N, Nishio K: Establishment of a CPT-11-resistant human ovarian cancer cell line. Anticancer Research 14:799-804, 1994
18. 18. Markman M: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10(4):513-514, 1992
19. 19. Manetta A, MacNeil C, Lyter JA, Scheffler B, Padczaski ES, Larson JE, Schein P: Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol Oncol 36:93-96, 1990
20. 20. Moore DH, Valea F, Grumpier LS, Fowler WC: Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian cancer. Gynecol Oncol 51:109-112, 1993
21. 21. Eckhardt S, Hernadi Z, Thurzo L, Telekes A, Sopkova B, Mechl Z, Pawlicki M, Kerpel-Fronius S: Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Oncology 47:289-295, 1990
22. 22. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant ovarian cancer. J CHn Oncol 12(1):60-63, 1994
23. 23. Markman M, Hakes T, Reichman B, Lewis JL, Rubin S, Jones W, Almadrones L, Hoskins W: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10(2):243-248, 1992
24. 24. Markman M: Ifosfamide in the treatment of ovarian cancer. Semin Oncol 23(3, Suppl 6):47-49, 1996
25. 25. Lund B, Neijt JP: Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 23(5):72-76, 1996
26. 26. Fleming GF, Waggoner SE, Rotmensch J, Skoog LA, Langhauser C: Phase II study of 96-hr continuous infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Gynecol Oncol 65:42-45, 1997